Trials / Recruiting
RecruitingNCT05290038
ARON-2 Study-Multicentric International Retrospective Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 367 (estimated)
- Sponsor
- Matteo Santoni · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The ARON-2 study retrospectively analyze patients treated with pembrolizumab as first-line therapy in patients platinum-unfit or as second-line therapy in patients progressed after previous platinum-based chemotherapy. The amendment has been designed to also analyze patients treated with enfortumab vedotin progressed to previous platinum-based chemotherapy and anti-PD-1/PD-L1 inhibitor.
Conditions
Timeline
- Start date
- 2022-02-17
- Primary completion
- 2023-12-31
- Completion
- 2027-09-30
- First posted
- 2022-03-22
- Last updated
- 2025-04-02
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT05290038. Inclusion in this directory is not an endorsement.